Search

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Registration

Register closed

Registration fee includes:

Access to all scientific and educational sessions of the meeting
Networking opportunities during breaks 
Coffee breaks on October 18-20 and lunch on October 19

All fees include VAT.

Read more

Publications

HemaSphere - the official open access journal of EHAHemaSphere is the official open access, peer-reviewed journal of EHA, supporting hematology researchers by offering a fast and constructive review process and low publication fees.

Read more

Nominate yourself

You can nominate yourself for an EHA Board role as long as you have:

Any type of EHA membership apart from healthcare-affiliated membership
Paid your annual membership fees
If you're unsure how to pay your annual membership fees, visit our renew your membership…

Read more

Abstract submission

Abstract procedureThe official abstract submission closed on March 1, 2025 (23:59 CET).

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more